title: Patterns of human papillomavirus DNA and antibody positivity in young males and females, suggesting a site-specific natural course of infection.
abstract: BACKGROUND
  To monitor the impact of human papillomavirus types 16 and 18 vaccine on HPV infection dynamics in the Netherlands, we started an ongoing study in sexually transmitted infection (STI) clinics in 2009. Here, we analyze baseline type-specific HPV DNA and HPV-specific antibody positivity rates.
  
  
  METHODS
  We enrolled 3569 men and women, 16-24 years of age, from 14 STI clinics, and estimated genital and anal HPV DNA and antibody positivity rates of 7 main carcinogenic HPV types. Generalized estimating equations regression analyses were applied to determine risk factors for, and associations between, type-specific HPV DNA and antibody positivity.
  
  
  RESULTS
  Genital HPV DNA positivity rates were higher in women than in men; anal HPV DNA was especially high in men who have sex with men (MSM). HPV antibody seropositivity rates were also highest in women and MSM. High-risk sexual behavior was predictive of both HPV DNA and antibody positivity. Despite a strong correlation in serological profiles for multiple HPV types, seropositivity was independently associated with homologous HPV DNA detection.
  
  
  CONCLUSIONS
  HPV DNA and antibody positivity rates are higher in women and MSM than in heterosexual men, but their association is similar across gender. This suggests a site-specific natural course of infection.
authors: Centre for Infectious Disease Control, National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands. rianne.vriend@rivm.nl
authors: Henrike J
authors: HJ
authors: Vriend
authors: Johannes A
authors: JA
authors: Bogaards
authors: Fiona R M
authors: FR
authors: van der Klis
authors: Mirte
authors: M
authors: Scherpenisse
authors: Hein J
authors: HJ
authors: Boot
authors: Audrey J
authors: AJ
authors: King
authors: Marianne A B
authors: MA
authors: van der Sande
mesh_terms: D000293:Adolescent; D001003:Anal Canal / Q000821:virology; D000914:Antibodies, Viral / Q000097:blood* / Q000276:immunology; D000918:Antibody Specificity; D002648:Child; D004279:DNA, Viral / Q000097:blood* / Q000235:genetics; D005260:Female; D005836:Genitalia, Female / Q000821:virology; D005837:Genitalia, Male / Q000821:virology; D005838:Genotype; D020010:Heterosexuality; D018451:Homosexuality, Male; D052162:Human papillomavirus 16 / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification* / Q000502:physiology*; D052161:Human papillomavirus 18 / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification* / Q000502:physiology*; D006801:Humans; D008297:Male; D009928:Organ Specificity; D030361:Papillomavirus Infections / Q000097:blood / Q000821:virology*; D055815:Young Adult
chemical_list: D000914:Antibodies, Viral; D004279:DNA, Viral
references: Sex Transm Dis. 2011 Oct;38(10):932-40
references: 21934568
references: Sex Transm Dis. 2008 Mar;35(3):276-82
references: 18091564
references: Vaccine. 2010 Aug 31;28(38):6247-55
references: 20643092
references: J Infect Dis. 2002 Nov 15;186(10):1396-402
references: 12404154
references: Lancet Oncol. 2009 Apr;10(4):321-2
references: 19350698
references: J Infect Dis. 2009 Apr 1;199(7):926-35
references: 19236279
references: J Infect Dis. 2000 Jun;181(6):1911-9
references: 10837170
references: Clin Infect Dis. 2008 Jun 1;46(11):1647-55
references: 18444790
references: Vaccine. 2011 Nov 8;29(48):9112-22
references: 21419773
references: J Infect Dis. 2007 Oct 15;196(8):1137-45
references: 17955431
references: J Infect Dis. 2009 Oct 1;200(7):1059-67
references: 19719390
references: Clin Vaccine Immunol. 2008 Sep;15(9):1387-90
references: 18632924
references: Cancer Res. 2001 Mar 1;61(5):1934-40
references: 11280749
references: J Clin Virol. 2009 Oct;46(2):107-11
references: 19665924
references: Int J Cancer. 1999 Jan 29;80(3):365-8
references: 9935175
references: Vaccine. 2012 Oct 19;30(47):6686-93
references: 22959981
references: Vaccine. 2006 Aug 31;24 Suppl 3:S3/1-10
references: 16949995
references: Epidemiology. 2011 Jul;22(4):505-15
references: 21540743
references: Lancet. 2009 Jul 25;374(9686):301-14
references: 19586656
references: Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):110-6
references: 14744741
references: Sex Transm Dis. 2012 Jan;39(1):72-8
references: 22183851
references: Virology. 2004 Jun 20;324(1):17-27
references: 15183049
references: J Infect Dis. 2011 Jul 15;204(2):209-16
references: 21673030
references: J Clin Virol. 2005 Mar;32 Suppl 1:S43-51
references: 15753011
references: J Infect Dis. 2012 Oct;206(8):1291-8
references: 22872732
references: Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):990-1002
references: 21378268
references: Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):159-69
references: 20056635
references: Sex Transm Infect. 2011 Feb;87(1):41-3
references: 20924049
references: Evid Based Med. 2011 Oct;16(5):157-8
references: 21561929